A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease

Klaudia Farkas, Tamás Molnár

Research output: Review article

Abstract

The introduction of biological agents has led to significant changes in the treatment of inflammatory bowel disease (IBD). The relatively high price of infliximab (IFX) and the expiration of the patents led to the introduction of biosimilar agents. CT-P13 was the first IFX biosimilar approved in the same indications as the reference product; however, the approval was based on randomized clinical trials conducted in patients with rheumatoid arthritis and ankylosing spondylitis. In the past 2-3 years, new findings from prospective observational studies supported the short-, medium-and long-Term clinical efficacy and safety of CT-P13 in patients with IBD. This review summarized the clinical use and efficacy of the first biosimilar IFX, CT-P13, in the treatment of IBD.

Original languageEnglish
Pages (from-to)107-117
Number of pages11
JournalImmunotherapy
Volume10
Issue number2
DOIs
Publication statusPublished - febr. 2018

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease'. Together they form a unique fingerprint.

  • Cite this